Cargando…

The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy

BACKGROUND: With the increasing number of agents active against cancer, advanced cancer patients including metastatic colorectal cancer (mCRC) patients may continue receiving palliative systemic anticancer therapy (PSAT) near the end-of-life. Validated palliative prognostic models, such as the Chuan...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsirafy, Samy A, Zaki, Omar, Sakr, Amr Y, Farag, Dina E, El-Sherief, Wessam A, Mohammed, Abha A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973493/
https://www.ncbi.nlm.nih.gov/pubmed/27559261
http://dx.doi.org/10.4103/0973-1075.185043
_version_ 1782446407007862784
author Alsirafy, Samy A
Zaki, Omar
Sakr, Amr Y
Farag, Dina E
El-Sherief, Wessam A
Mohammed, Abha A
author_facet Alsirafy, Samy A
Zaki, Omar
Sakr, Amr Y
Farag, Dina E
El-Sherief, Wessam A
Mohammed, Abha A
author_sort Alsirafy, Samy A
collection PubMed
description BACKGROUND: With the increasing number of agents active against cancer, advanced cancer patients including metastatic colorectal cancer (mCRC) patients may continue receiving palliative systemic anticancer therapy (PSAT) near the end-of-life. Validated palliative prognostic models, such as the Chuang's prognostic scale (CPS), may be helpful in identifying mCRC patients with limited survival who are unlikely to benefit from PSAT. AIM: To test the ability of the CPS to predict the survival of mCRC under treatment with PSAT. METHODS: CPS was prospectively assessed in 36 mCRC patients who were receiving PSAT. The scale is based on eight items: ascites, edema, cognitive impairment, liver and lung metastases, performance status, tiredness, and weight loss. The total CPS score ranges from 0 to 8.5 with the higher score indicating worse prognosis. RESULTS: Patients were divided into two groups using a CPS cutoff score of 5, Group 1 with a CPS score ≤5 and Group 2 with a CPS score >5. Using this cutoff value, 3-month mortality was predicted with a positive predictive value of 71%, a negative predictive value of 77%, a sensitivity of 67%, a specificity of 81% and an overall accuracy of 75%. Group 1 patients had a longer median survival of 149 days (95% confidence interval [CI]: 82-216) in comparison to Group 2 patients who had a median survival of 61 days (95% CI: 35-87). The difference in survival was statistically significant (P = 0.01). CONCLUSION: CPS may be useful in identifying mCRC patients with limited survival who are unlikely to benefit from PSAT.
format Online
Article
Text
id pubmed-4973493
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-49734932016-08-24 The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy Alsirafy, Samy A Zaki, Omar Sakr, Amr Y Farag, Dina E El-Sherief, Wessam A Mohammed, Abha A Indian J Palliat Care Original Article BACKGROUND: With the increasing number of agents active against cancer, advanced cancer patients including metastatic colorectal cancer (mCRC) patients may continue receiving palliative systemic anticancer therapy (PSAT) near the end-of-life. Validated palliative prognostic models, such as the Chuang's prognostic scale (CPS), may be helpful in identifying mCRC patients with limited survival who are unlikely to benefit from PSAT. AIM: To test the ability of the CPS to predict the survival of mCRC under treatment with PSAT. METHODS: CPS was prospectively assessed in 36 mCRC patients who were receiving PSAT. The scale is based on eight items: ascites, edema, cognitive impairment, liver and lung metastases, performance status, tiredness, and weight loss. The total CPS score ranges from 0 to 8.5 with the higher score indicating worse prognosis. RESULTS: Patients were divided into two groups using a CPS cutoff score of 5, Group 1 with a CPS score ≤5 and Group 2 with a CPS score >5. Using this cutoff value, 3-month mortality was predicted with a positive predictive value of 71%, a negative predictive value of 77%, a sensitivity of 67%, a specificity of 81% and an overall accuracy of 75%. Group 1 patients had a longer median survival of 149 days (95% confidence interval [CI]: 82-216) in comparison to Group 2 patients who had a median survival of 61 days (95% CI: 35-87). The difference in survival was statistically significant (P = 0.01). CONCLUSION: CPS may be useful in identifying mCRC patients with limited survival who are unlikely to benefit from PSAT. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4973493/ /pubmed/27559261 http://dx.doi.org/10.4103/0973-1075.185043 Text en Copyright: © Indian Journal of Palliative Care http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Alsirafy, Samy A
Zaki, Omar
Sakr, Amr Y
Farag, Dina E
El-Sherief, Wessam A
Mohammed, Abha A
The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy
title The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy
title_full The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy
title_fullStr The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy
title_full_unstemmed The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy
title_short The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy
title_sort use of the chuang's prognostic scale to predict the survival of metastatic colorectal cancer patients receiving palliative systemic anticancer therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973493/
https://www.ncbi.nlm.nih.gov/pubmed/27559261
http://dx.doi.org/10.4103/0973-1075.185043
work_keys_str_mv AT alsirafysamya theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT zakiomar theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT sakramry theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT faragdinae theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT elsheriefwessama theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT mohammedabhaa theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT alsirafysamya useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT zakiomar useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT sakramry useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT faragdinae useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT elsheriefwessama useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy
AT mohammedabhaa useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy